Abstract
In a structured treatment interruption (STI) trial, 3 of 23 patients in a CD4 cell count-guided treatment arm developed recurring thrombocytopenia associated with the interruption of antiretroviral therapy. All 3 patients had slightly low or normal platelet counts before initiating antiretroviral therapy. STI may play a role in inducing thrombocytopenia in patients with human immunodeficiency virus infection.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
CD4 Lymphocyte Count
-
Drug Administration Schedule
-
HIV Infections / drug therapy*
-
HIV Infections / enzymology
-
HIV Protease Inhibitors / adverse effects
-
HIV Protease Inhibitors / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Platelet Count
-
Randomized Controlled Trials as Topic
-
Recurrence
-
Reverse Transcriptase Inhibitors / adverse effects
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Thrombocytopenia / etiology*
Substances
-
HIV Protease Inhibitors
-
Reverse Transcriptase Inhibitors